$757M and 5 years lat­er, Cel­gene aban­doned a biotech part­ner, trig­ger­ing lay­offs

Two months af­ter we broke the sto­ry that For­ma Ther­a­peu­tics had axed R&D staff in a ma­jor re­or­ga­ni­za­tion of the com­pa­ny, found­ing CEO Steve Tre­gay is now join­ing the ex­o­dus. He’s be­ing re­placed at the helm by Genen­tech vet and chief strat­e­gy of­fi­cer Frank Lee.

While Tre­gay con­firmed to me in Jan­u­ary that For­ma had cut 61 staffers in what he called a strate­gic turn to­ward the clin­ic with their pipeline drugs, he de­clined to say what had hap­pened to their foun­da­tion deal with Cel­gene. He promised an ac­count­ing lat­er in Q1.

But it was fun­da­men­tal­ly fin­ished, along with the buy­out op­tion that Cel­gene had forged for it­self in 2014.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER